BRAIN SCAN NEWS

HTH Worldwide Introduces mPassport(sm), Mobile Health and Safety
PR Newswire

RADNOR, Pa., July 17 /PRNewswire/ -- HTH Worldwide, a global health and safety services company, today introduced mPassport(sm), a mobile health information tool for global travelers. mPassport subscribers have convenient access to HTH Worldwide's databases of global health and safety information when they are on the go and on their mobile phone. Subscribers can access mPassport at www.mPassport.com/mobile on their mobile phones or at www.mPassport.com on their computers.

Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
PR Newswire

ROCHESTER, N.Y., July 17 /PRNewswire-USNewswire/ -- Strong National Museum of Play is pleased to announce the launch in mid-July of the American Journal of Play, the first interdisciplinary journal anywhere dedicated solely to the study of play.

Video: Allen Institute for Brain Science Unveils World's First Genome-Wide Spinal Cord Atlas
PR Newswire

WASHINGTON, July 17 /PRNewswire/ -- The Allen Institute for Brain Science today unveiled the groundbreaking Allen Spinal Cord Atlas, the world's first genome-wide map of the mouse spinal cord. Researchers can immediately access the free online data to advance their research surrounding spinal cord diseases and disorders.

New Stroke Guidelines for Children - WebMD
Google

By Stephanie Watson July 17, 2008 -- Strokes don't only occur in older adults -- children can have them too. Because stroke can lead to brain damage and death, the American Heart Association/American Stroke Association has for the first time released ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
PR Newswire

- PFS data from Neuradiab(TM) compares favorably to data from other

Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimer's Disease
PR Newswire

SAN FRANCISCO, July 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of the results of its first Alzheimer's disease pivotal clinical trial of the investigational drug Dimebon in the July 19, 2008 issue of The Lancet. In this double-blind, placebo-controlled trial, patients with mild-to-moderate Alzheimer's disease treated with Dimebon experienced statistically significant improvements compared to placebo in all the key aspects of the disease: memory and thinking, activities of daily living, behavior and overall function.

Bankers Life and Casualty Company Supports Alzheimer's Association With More Than $300,000
PR Newswire

CHICAGO, July 17 /PRNewswire/ -- Through its annual street corner fundraiser and a separate corporate donation, Bankers Life and Casualty Company is supporting the Alzheimer's Association with over $300,000.

New weight-loss device may trick brain and turn off the appetite - Tulsa World
Google

By MAURA LERNER Star Tribune (Minneapolis) MINNEAPOLIS — Dr. Sayeed Ikramuddin is no stranger to weight-loss surgery. He's done it at least 3000 times. ...

Emergency Nurses Association, American Academy of Emergency Medicine Release Statement Denouncing 'Mystery Shoppers' in Emergency Departments
PR Newswire

DES PLAINES, Ill., July 16 /PRNewswire/ -- The Emergency Nurses Association (ENA) today released a statement denouncing the use of "Mystery Shoppers," people who are sent to the emergency department with a fake injury or illness in order to test customer-service. The statement, endorsed by the American Academy of Emergency Medicine (AAEM), states the practice is not only dangerous and detrimental to quality care, but unnecessary since other more effective, less intrusive methods exist to gauge customer satisfaction.

Peptimmune Announces the Second Close of Series D Private Financing
PR Newswire

CAMBRIDGE, Mass., July 16 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a second close of $8.9 million of its Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, and its Chairman of the Board. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

‹ First  < 269 270 271 272 273 >  Last ›

Browse by Category


Browse by Condition